25 years of the use of domestic original antiretroviral drugs in first-line ART regimens of HIV-infection; [25 лет применения отечественных оригинальных антиретровирусных препаратов в схемах первой линии терапии ВИЧ-инфекции]

The article presents an overview of studies conducted by the staff of the Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing for 25 years and devoted to the use of original domestic antiretroviral drugs in the treatment regimens of patients with HIV infection. The first domestic drug Phosphazid (PhAZT – nucleoside HIV reverse transcriptase inhibitor, NRTI) was registered in 1999, and the second – Elsulfavirin (ESV – non-nucleoside HIV reverse transcriptase inhibitor) – in 2017. In the last 3 years, data have been obtained on the high efficacy and good tolerability of a completely domestic therapy regimen (PhAZT/Lamivudine + ESV). Currently, phase III studies of a new original domestic drug (6HP, Amcafovir – NRTI) with a single dose per day are being conducted. Also, studies of the I–II phase of the study of the prolonged form of ESV (VM-1500 LAI) with a frequency of taking the drug 1 time per month with intramuscular administration have been completed. © 2023 Geotar Media Publishing Group. All Rights Reserved.